Athenecia Faggins of Minaris Advanced Therapies discusses raw material qualification, supplier management, testing, and risk control for advanced therapy manufacturing.
Feature|Videos|July 29, 2024
Enzene Expands Into the US and Will Provide State-of-the-Art Fully Connected Continuous Manufacturing Services to Pharma and Biotech Companies
Author(s)Enzene Biosciences Ltd.
Dr Himanshu Gadgil, CEO, Enzene Biosciences Ltd., describes the rationale for expanding its services, including its patented EnzeneX™ continuous manufacturing technology platform, to emerging innovative, US-based biotech firms looking to benefit from the in-depth expertise in continuous manufacturing.
Watch the video and learn more:
- What distinguishes EnzeneX™ technology from other existing continuous processing manufacturing methods.
- Types of customers that can benefit from EnzeneX™ technology and other Enzene Biosciences Ltd. services.
- Updates pertaining to the launch of Enzene's first US-based manufacturing plant.
Related to this article
FDA compliance officers detailed 2026 guidance updates, online drug sale enforcement, and a first-of-its-kind AI-related warning letter at the PDA/FDA Joint Regulatory Conference.
Sanofi’s Jack Prior discusses how biopharmaceutical manufacturers can assess whether process data is ready for human and AI use, and the role of data quality, accessibility, governance, and AI in manufacturing.
Panelists from FDA, Genentech, and Minaris discussed raw material risk, supplier oversight, and at-risk release strategies for advanced therapies at the PDA/FDA Joint Regulatory Conference.
Dualitas will screen over 300,000 bispecific combinations for Roche, backing a deal worth up to $1 billion in immunology research.
FDA's Francis R.W. Godwin (CDER) and Kathleen Jones, PhD (CBER) detail a record pace of drug warning letters and the CGMP deficiencies most commonly cited in biologics facility inspections.
Sanofi's Dr Jack Prior detailed a data maturity framework for biologics manufacturing, while FDA and Gilead panelists debated risk-based AI validation.
FDA's consumer safety officer, Jason Chancey, detailed real inspection findings, such as taped gaskets and delayed retesting, behind sterile facility deficiencies.